<DOC>
	<DOCNO>NCT01791452</DOCNO>
	<brief_summary>Non-alcoholic fatty liver disease ( NAFLD ) world-wide problem global prevalence estimate 1.5 billion people . It characterise significant diversity phenotypic heterogeneity . Morbidity rate estimate 20 % 30 % Western adult , increase 90 % patient morbidly obese diabetic . Risk factor non-obese NAFLD patient especial practical theoretical importance . Cholesterol Ester Storage Disease ( CESD ) autosomal recessive chronic disease variable phenotype , cause deficiency lysosomal acid lipase ( LAL ) characterize accumulation fat tissue organ . Hepatic accumulation fat disorder cause hepatomegaly vary degree damage vary steatosis fibrosis , elevated aminotransaminases , isolate splenomegaly . Since contribution LAL deficiency non-obese NAFLD poorly understand , investigator propose evaluate association NAFLD LAL deficiency prospective study population .</brief_summary>
	<brief_title>Novel Association Cholesterol Ester Storage Disease Due Lysosomal Acid Lipase Deficiency Non-Alcoholic Fatty Liver Disease : A Prospective Clinical Study</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Wolman Disease</mesh_term>
	<mesh_term>Cholesterol Ester Storage Disease</mesh_term>
	<criteria>Age 1880 year ; BMI 2540 ; Fatty liver disease ( bright liver , hepatomegaly ultrasound ( Liver span &gt; 15 cm mid clavicle line ) , splenomegaly ( &gt; 13 cm ) . Alcohol abuse &gt; 30 gm/day , &gt; 70 gram per week ; Soft drink abuse ; Drugs know cause fatty liver ; Chronic hepatitis ( B C ) ; Biliary liver disease ; Autoimmune hepatitis ; HIV ; Genetic/Metabolic liver disease ( Wilson , alpha1 antitrypsin , CF ) ; Failure give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>